IP Library Granted Patent US 9,394,234
Granted Patent B2
US 9,394,234 · App. 14/319,996 · Granted Jul 19, 2016

Lipid formulations

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,394,234
App. No.
14/319,996
Granted
Jul 19, 2016
Kind
B2
Abstract

The invention features a cationic lipid of formula I, an improved lipid formulation comprising a cationic lipid of formula I and corresponding methods of use. Also disclosed are targeting lipids, and specific lipid formulations comprising such targeting lipids.

Claims (11)

1. A method of making a cationic lipid of formula I, or a pharmaceutically acceptable salt thereof,

comprising reacting dilinoleyl methanol with dimethylaminobutyric acid, or a salt thereof, under conditions to provide the cationic lipid of formula I, or a pharmaceutically acceptable salt thereof.

2. The method of claim 1 , wherein the dilinoleyl methanol is reacted with a hydrochloride salt of dimethylaminobutyric acid under conditions to provide a compound of formula I, or a pharmaceutically acceptable salt thereof.

3. The method of claim 1 , wherein dilinoleyl methanol is reacted with a salt of dimethylaminobutyric acid under conditions that include EDCI, DMAP and DIPEA.

4. The method of claim 1 , further comprising purifying the compound of formula I, or a pharmaceutically acceptable salt thereof.

5. The method of claim 4 , wherein the compound of formula I, or a pharmaceutically acceptable salt thereof, is purified using Flash column chromatography.

6. The method of claim 1 , further comprising providing the dilinoleyl methanol by converting linoleyl bromide to dilinoleyl methanol.

7. The method of claim 6 , wherein the converting is carried out by reacting linoleyl bromide with magnesium followed by water to provide a resulting mixture that comprises dilinoleyl methanol.

8. The method of claim 7 , further comprising treating the resulting mixture with a base to provide dilinoleyl methanol.

9. The method of claim 8 , further comprising purifying the dilinoleyl methanol.

10. The method of claim 9 , wherein the dilinoleyl methanol is purified using column chromatography.

Assignments (5)
SECURITY INTEREST Recorded Oct 1, 2025
From: ALNYLAM PHARMACEUTICALS, INC.; SIRNA THERAPEUTICS, INC.
To: BANK OF AMERICA, N.A.
Reel/Frame 072996/0337 →
MERGER AND CHANGE OF NAME Recorded Jul 27, 2018
From: PROTIVA BIOTHERAPEUTICS INC.; ARBUTUS BIOPHARMA CORPORATION
To: ARBUTUS BIOPHARMA CORPORATION
Reel/Frame 046640/0764 →
CHANGE OF NAME Recorded May 19, 2016
From: TEKMIRA PHARMACEUTICALS CORPORATION
To: ARBUTUS BIOPHARMA CORPORATION
Reel/Frame 038646/0652 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 31, 2014
From: ALNYLAM PHARMACEUTICALS, INC.
To: TEKMIRA PHARMACEUTICALS CORPORATION
Reel/Frame 033435/0126 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 31, 2014
From: CHEN, JIANXIN; ANSELL, STEVEN; AKINC, AKIN; DORKIN, JOSEPH ROBERT; QIN, XIAOJUN; CANTLEY, WILLIAM; MANOHARAN, MUTHIAH; RAJEEV, KALLANTHOTTATHIL G.; NARAYANANNAIR, JAYAPRAKASH K.; JAYARAMAN, MUTHUSAMY
To: ALNYLAM PHARMACEUTICALS, INC.
Reel/Frame 033435/0159 →